The oxygenating constituent of 3,6-diketocamphane monooxygenase from the CAM plasmid of Pseudomonas putida: the first crystal structure of a type II Baeyer-Villiger monooxygenase. by Isupov, MN et al.
electronic reprint
ISSN: 1399-0047
journals.iucr.org/d
The oxygenating constituent of 3,6-diketocamphane
monooxygenase from the CAM plasmid of Pseudomonas
putida: the first crystal structure of a type II Baeyer–Villiger
monooxygenase
Michail N. Isupov, Ewald Schro¨der, Robert P. Gibson, Jean Beecher,
Giuliana Donadio, Vahid Saneei, Stephlina A. Dcunha, Emma J. McGhie,
Christopher Sayer, Colin F. Davenport, Peter C. Lau, Yoshie Hasegawa,
Hiroaki Iwaki, Maria Kadow, Kathleen Balke, Uwe T. Bornscheuer, Gleb
Bourenkov and Jennifer A. Littlechild
Acta Cryst. (2015). D71, 2344–2353
IUCr Journals
CRYSTALLOGRAPHY JOURNALS ONLINE
This open-access article is distributed under the terms of the Creative Commons Attribution Licence
http://creativecommons.org/licenses/by/2.0/uk/legalcode, which permits unrestricted use, distribution, and
reproduction in any medium, provided the original authors and source are cited.
Acta Cryst. (2015). D71, 2344–2353 Isupov et al. · Type II Baeyer–Villiger monooxygenase
research papers
2344 http://dx.doi.org/10.1107/S1399004715017939 Acta Cryst. (2015). D71, 2344–2353
Received 22 June 2015
Accepted 24 September 2015
Edited by M. Schiltz, Fonds National de la
Recherche, Luxembourg
Keywords: FMN-dependent monooxygenase;
protein structure; industrial biocatalysis.
PDB references: type II Baeyer–Villiger
monooxygenase, apo, 5aec; FMN complex,
4uwm
Supporting information: this article has
supporting information at journals.iucr.org/d
The oxygenating constituent of 3,6-diketocamphane
monooxygenase from the CAM plasmid of
Pseudomonas putida: the first crystal structure of a
type II Baeyer–Villiger monooxygenase
Michail N. Isupov,a Ewald Schro¨der,a Robert P. Gibson,a Jean Beecher,a Giuliana
Donadio,a Vahid Saneei,a Stephlina A. Dcunha,a Emma J. McGhie,a Christopher
Sayer,a Colin F. Davenport,a Peter C. Lau,b Yoshie Hasegawa,c Hiroaki Iwaki,c
Maria Kadow,d Kathleen Balke,d Uwe T. Bornscheuer,d Gleb Bourenkove and
Jennifer A. Littlechilda*
aThe Henry Wellcome Building for Biocatalysis, Biosciences, College of Life and Environmental Sciences, University of
Exeter, Stocker Road, Exeter EX4 4QD, England, bBiotechnology Research Institute, National Research Council Canada,
6100 Royalmount Avenue, Montreal, QC H4P 2R2, Canada, cDepartment of Biotechnology, Faculty of Engineering,
Kansai University, Japan, dDepartment of Biotechnology and Enzyme Catalysis, Institute of Biochemistry, Greifswald
University, Felix-Hausdorff-Strasse 4, 17487 Greifswald, Germany, and eEuropean Molecular Biology Laboratory (EMBL),
Hamburg Outstation, Notkestrasse 85, 22607 Hamburg, Germany. *Correspondence e-mail: j.a.littlechild@exeter.ac.uk
The three-dimensional structures of the native enzyme and the FMN complex of
the overexpressed form of the oxygenating component of the type II Baeyer–
Villiger 3,6-diketocamphane monooxygenase have been determined to 1.9 A˚
resolution. The structure of this dimeric FMN-dependent enzyme, which is
encoded on the large CAM plasmid of Pseudomonas putida, has been solved by
a combination of multiple anomalous dispersion from a bromine crystal soak
and molecular replacement using a bacterial luciferase model. The orientation
of the isoalloxazine ring of the FMN cofactor in the active site of this TIM-barrel
fold enzyme differs signiﬁcantly from that previously observed in enzymes of the
bacterial luciferase-like superfamily. The Ala77 residue is in a cis conformation
and forms a -bulge at the C-terminus of -strand 3, which is a feature observed
in many proteins of this superfamily.
1. Introduction
The use of enzymes in commercial biocatalysis is of increasing
importance for the ﬁne-chemical and pharmaceutical indus-
tries, with the number of new drugs produced in this way due
to increase dramatically over the next few years (Wohlgemuth,
2010; Bornscheuer et al., 2012; Reetz, 2013). The application
of enzymes has considerable advantages in that the process
is environmentally friendly and enzymes have the ability to
produce single enantiomeric products, which are of value as
chiral building blocks for new drug molecules (Lilly et al., 1996;
Littlechild et al., 2007).
The Baeyer–Villiger oxidation reaction (Baeyer & Villiger,
1899) is an important reaction for synthetic organic chemistry
in which linear/cyclic ketones react with peroxy acids to
produce a corresponding ester/lactone. The application of the
Baeyer–Villiger reaction for the chemical synthesis of anti-
biotics, steroids and pheromones has been reviewed by Krow
(1993). The purity and stereospeciﬁcity of the reaction
products required by the pharmaceutical industry is difﬁcult to
achieve by traditional chemical processes owing to the high
reactivity of peracids (Roberts & Wan, 1998). The use of
peracids and solvents on a large scale is not environmentally
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friendly. Therefore, there is increasing interest from industry
in enzymes that can carry out a Baeyer–Villiger oxidation
reaction (Alphand et al., 2003).
Several microorganisms can produce NAD(P)H-dependent
ﬂavoenzymes capable of catalyzing Baeyer–Villiger reactions
(Leisch et al., 2011; Balke et al., 2012), which use a stable
ﬂavin–peroxide intermediate to attack the carbonyl C atom of
the substrate in a reaction identical to the equivalent non-
enzymatic reaction. These enzymes are called Baeyer–Villiger
monooxygenases (BVMOs) and are classiﬁed into two main
types depending on the ﬂavin cofactor. The more studied type
I BVMOs are proteins utilizing the FAD cofactor, which is
reduced by an NADPH bound to the same polypeptide chain.
The ﬁrst type I BVMO crystal structure was reported for
the phenylacetone monooxygenase from Thermobiﬁda fusca
(Malito et al., 2004). Type II BVMOs utilize a FMN cofactor,
which is reduced by a separate NADH dehydrogenase
enzyme. These enzymes have been relatively understudied
compared with the type I enzymes owing to their more
complex multi-enzyme structure. The substrate speciﬁcity of
type II BVMOs is different from the type I enzymes and they
are increasingly important for commercial biocatalysis since
they have the ability to oxidize bicyclic lactones (Alphand et
al., 2003) and because they utilize the cheaper cofactor
NADH.
It has been known for some time that the bacterium Pseu-
domonas putida NCIMB 10007 is able to grow on either
enantiomer of the natural bicyclic monoterpene camphor as
the sole carbon source (LeGall et al., 1963). The oxidative
degradation pathway of camphor requires two enantiocom-
plementary type II BMVOs (Conrad et al., 1965), 2,5-diketo-
camphane 1,2-monooxygenase (2,5-DKMO; EC 1.14.13.162)
and 3,6-diketocamphane 1,6-monooxygenase (3,6-DKMO; EC
1.14.13.–), which catalyse the NADH-dependent lactonization
of diketocamphane stereoisomers (2,5- and 3,6-diketocam-
phane). The latter are intermediates in the oxidative degra-
dation pathway of (+)- and ()-camphor, respectively (Fig. 1).
Both DKMOs are located on the large CAM plasmid
harboured in P. putida and are induced when either racemic
camphor or one of its stereoisomers are present in the growth
medium (Shaham et al., 1973). The DKMO enzymes have
been reported to be built up from a dimeric oxygenating
component and a loosely associated NADH dehydrogenase
(Jones et al., 1993). Both the 2,5-DKMO and 3,6-DKMO
oxygenating components have sequence similarity to bacterial
luciferases (McGhie, 1998) and bear little similarity to type I
BVMOs. The molecular masses of the 2,5-DKMO and
3,6-DKMO monomers are 40.7 and 42.3 kDa, respectively
(McGhie et al., 1998).
The two DKMO enzymes have been shown to carry out
oxygenation reactions with a variety of natural ketones and
their synthetic analogues using partially puriﬁed preparations
of the wild-type enzyme (Grogan, Roberts & Willetts, 1993;
Grogan, Roberts, Wan et al., 1993; Grogan et al., 1994; Gagnon
et al., 1994, 1995), where a mixture of both DKMOs was called
MO1. This preparation was also able to utilize a range of aryl
alkyl and alkyl alkyl sulﬁdes. The two DKMOs can use natural
and synthetic ketones with distinct enantioselectivity and they
have been exploited in key reactions for the chemoenzymatic
synthesis of commercially useful products (Grogan et al., 1992;
Grogan, Roberts &Willetts, 1993; Grogan, Roberts, Wan et al.,
1993; Gagnon et al., 1994, 1995). The results of the different
ketone and sulﬁde biotransformations were used to produce
simple models for the substrate-binding pockets of both
enzymes, which implied that there were differences between
them (Beecher & Willetts, 1998).
The mechanism of enantioselectivity for the hydroxyl–
peroxide rearrangement taking place in the BVMO active site
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Figure 1
The camphor-degradation pathway (adapted from McGhie et al., 1998).
The following enzymes are indicated: (1) 5-exo-hydroxylase (P450CAM),
(2) and (3) exo-hydroxycamphor dehydrogenases, (4) 3,6-DKMO, (5)
2,5-DKMO.
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was proposed by Kelly (1996) to be owing to diastereofacial
selection by the ﬂavin cofactor. Type II BVMOs were attrib-
uted to the R group in relation to the re-face attachment of the
hydroperoxide to the ﬂavin coenzyme.
Initial structural characterization studies of 3,6-DKMO
by our group were with the native enzyme puriﬁed from
camphor-induced P. putida cell cultures. This was the only
isozyme able to be puriﬁed in sufﬁcient quantities for crys-
tallization (McGhie et al., 1998). Only preliminary structural
studies have been reported by us to date for the type II
enzymes (McGhie et al., 1998; Isupov & Lebedev, 2008).
Detailed structural and mechanistic comparisons of the two
DKMO isozymes, which have 45% sequence identity (Kadow
et al., 2012), and knowledge of their active sites will enable
rationalization of their substrate speciﬁcity and their potential
optimization by site-directed mutagenesis to use new indust-
rially relevant substrates.
Multiple attempts to overexpress 3,6-DKMO in Escherichia
coli were unsuccessful until the application of the Takara
chaperone system (Kadow et al., 2012). Using 3,6-DKMO
produced using this expression system has allowed further
protein crystals to be grown of the oxygenating subunit in both
the apo form and in the presence of the weakly bound FMN
cofactor. This has allowed the location of the bound cofactor
and a comparison between the native enzyme and cofactor-
complex structures to be carried out.
2. Experimental
2.1. Materials
All reagents were obtained from Sigma–Aldrich, Buchs,
Switzerland unless otherwise stated. The chromatography
columns were obtained from GE Healthcare (Little Chalfont,
England).
2.2. Enzyme purification
The original puriﬁcation of the native 3,6-DKMO from 20 l
batches of camphor-induced cells of P. putida NCIMB 10007
was reported by us previously (McGhie et al., 1998; McGhie &
Littlechild, 1996). The cells were harvested by centrifugation
and disrupted by sonication. After the removal of cell debris,
an ammonium sulfate precipitation step was followed by
dialysis in buffer A [20 mM KH2PO4/K2HPO4 pH 7.1, 6 mM
-mercaptoethanol, 0.1 mM EDTA, 10 mM phenylmethyl-
sulfonylﬂuoride (PMSF), 20 mM benzamidine (BAM)]. The
protein was applied onto a Fast Flow Q anion-exchange
chromatography column and eluted with a linear gradient of
0–0.45M potassium chloride in buffer A. After dialysis in
buffer A, the protein was applied onto a Mono Q anion-
exchange column and eluted with a linear gradient of 0–
0.45M potassium chloride in buffer A. This was followed by
size-exclusion chromatography in buffer A containing 5%
ammonium sulfate using a Superose 12 gel-ﬁltration column.
The fractions containing native 3,6-DKMOwere monitored by
NADH consumption at 340 nm and by analysis of the products
of the reaction by gas chromatography (McGhie et al., 1998).
Recombinant 3,6-DKMO was puriﬁed from E. coli BL21
(DE3) cells (Novagen, Darmstadt, Germany) harbouring the
pET-28b (Novagen) vector with the 3,6-DKMO gene and the
plasmid pGro7 of the Takara Chaperone Plasmid Set (Takara,
Saint-Germain-en-Laye, France) grown in LB medium
containing 30 mg ml1 kanamycin and 30 mg ml1 chlor-
amphenicol at 37C to an optical density at 600 nm of 0.5–0.6
(Kadow et al., 2012). The culture was transferred to 20C and
the chaperones were induced by the addition of 2 mg ml1
l-arabinose and incubated for 30 min. Protein expression was
induced with 1 mM isopropyl -d-1-thiogalactopyranoside for
4 h at 20C. The cells were harvested by centrifugation at
20 000g. The cell paste from a 2 l culture was resuspended in
buffer B (20 mMKH2PO4/K2HPO4 pH 7.1, 6 mM -mercapto-
ethanol, 0.1 mM EDTA, 10 mM PMSF) at a concentration of
10%(w/v). Sonication was carried out using a Soniprep 150
(MSE UK Ltd, Lower Sydenham, England) followed by
centrifugation at 20 000g to remove precipitated protein and
cell debris. The N-terminally hexahistidine-tagged protein was
puriﬁed on a HiLoad nickel column using a linear gradient of
0–1M imidazole in buffer B. The enzyme was further puriﬁed
by gel ﬁltration on a Superdex 200 gel-ﬁltration column using
buffer B containing 0.1M NaCl.
2.3. Crystallization
Crystals of native 3,6-DKMO were grown at room
temperature by the vapour-diffusion technique using puriﬁed
protein at 10 mg ml1 mixed in equal volumes with 50 mM
PIPES pH 6.5, 50% ammonium sulfate (McGhie et al., 1998).
These crystals were ﬂash-cooled in liquid N2 after a short soak
in a cryoprotectant consisting of 30%(v/v) glycerol, 50 mM
PIPES pH 6.5, 55% ammonium sulfate.
The overexpressed 3,6-DKMO protein was concentrated
using a 10 kDa membrane Vivaspin (Vivascience, Massachu-
setts, USA). Microbatch crystallization trials were set up with
an Oryx 6 crystallization robot (Douglas Instruments,
Hungerford, England) using the Morpheus and JCSG+
screens (Molecular Dimensions, Newmarket, England) and
protein solution at 7 mg ml1 containing 20 mM FMN, 5 mM
NADH and 5 mM ()-camphor. The droplet consisted of a
50:50 ratio of protein solution to precipitant ratio and was
covered with a 50:50 mixture of silicone and parafﬁn oils. The
best crystals were ﬂash-cooled in liquid N2 after a 30 s soak
in a cryoprotectant consisting of 100 mM HEPES pH 7.0,
30%(v/v) PEG 200, 16% PEG 3350, 100 mM NaCl, 20 mM
FMN.
2.4. Data collection
The native 3,6-DKMO data were collected to 1.9 A˚ reso-
lution (Table 1) at 100 K at station BW7B at the EMBL
Outstation at DESY, Hamburg, Germany using a MAR345
image-plate detector (MAR Research, Norderstedt,
Germany). Three-wavelength MAD data sets were collected
at the Br K edge for the crystal of the native enzyme, which
was soaked for 1 min in a cryoprotectant consisting of 1M
NaBr for Br anomalous phasing (Dauter et al., 2000). These
research papers
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data were collected at 100 K at station BW6 at the Max Planck
Institute at DESY, Hamburg, Germany (Table 1) using a
MAR165 CCD detector (MAR Research). The data were
processed using the DENZO suite of programs (Otwinowski
& Minor, 1997).
Data for the complex of overexpressed 3,6-DKMO with
FMN were collected at 100 K on beamline I04-1 at the
Diamond Synchrotron light source (Oxford, England) using a
PILATUS detector (Dectris, Baden, Switzerland). The
complex data were processed and the native apo data were
reprocessed using XDS (Kabsch, 2010) in the xia2 (Winter et
al., 2013) pipeline. Further data and model manipulation was
carried out using the CCP4 suite of programs (Winn et al.,
2011).
2.5. Structure determination
The structure of native apo 3,6-DKMO was solved by a
combination of MR, Br-soak MAD and density modiﬁcation,
as previously described in Isupov & Lebedev (2008). MR trials
were performed using a synthetic 2 dimer of the bacterial
luciferase from Vibrio harveyi (16% sequence identity; Fisher
et al., 1996). An exhaustive translation search in MOLREP
(Vagin & Teplyakov, 2010) was conducted for all possible
orientations of the dimeric polyalanine model (Lebedev et al.,
2008) in which the orientation of its molecular dyad coincided
with orientation of the noncrystallographic twofold axis
determined from the self-rotation function at ’ = 78.4,  =
40.8,  = 180.0. A convincing translation-function solution
for a single orientation was subjected to rigid-body reﬁnement
in MOLREP (Vagin et al., 1998) and positional reﬁnement in
REFMAC5 (Murshudov et al., 2011). The 23 Br sites were
located in the anomalous difference Fourier synthesis using
phases obtained by multi-crystal averaging with DMMULTI
(Cowtan, 2010) and were used in MAD phasing with
MLPHARE (Otwinowski, 1991). While anomalous substruc-
ture search programs such as SHELXD (Sheldrick, 2010) can
research papers
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Table 1
Summary of data-collection, phasing and reﬁnement statistics.
Values in parentheses are for the outer resolution shell.
Native bromide soak
FMN complex Native Peak† Inﬂection† Remote†
Data collection
Space group P212121 P212121 P212121
Unit-cell parameters (A˚) a = 72.8, b = 82.8, c = 149.9 a = 55.0, b = 93.3, c = 161.9 a = 54.9, b = 93.3, c = 140.8
VM (A˚
3 Da1) 2.67 2.46 2.13
Beamline I04-1, Diamond BW7B, DESY BW6, DESY
Wavelength (A˚) 0.9200 0.8443 0.9177 0.9201 0.8500
Resolution (A˚) 55.60–1.90 (1.95–1.90) 20.44–1.93 (1.98–1.93) 13.00–2.70 (2.75–2.70) 13.00–2.75 (2.80–2.75) 13.00–2.45 (2.49–2.45)
Completeness (%) 99.5 (97.8) 98.9 (88.3) 99.1 (98.0) 99.3 (99.4) 97.1 (88.6)
Rmerge‡ 0.085 (0.95) 0.127 (0.686) 0.087 (0.253) 0.091 (0.211) 0.113 (0.319)
hIi/h(I)i 14.9 (2.0) 9.9 (2.0) 14.9 (2.8) 17.2 (6.3) 9.5 (2.6)
Multiplicity 6.7 (6.8) 3.9 (3.4) 3.2 3.2 2.2
Wilson B factor (A˚2) 34.7 27.5 33.9 34.5 37.8
Phasing
No. of sites 14
Phasing power§ 1.28
Rcullis} 0.72
FOM†† 0.26
Reﬁnement
Resolution (A˚) 55.60–1.90 10.44–1.93
No. of reﬂections 71728 59253
Rwork/Rfree‡‡ (%) 18.5/22.1 17.1/22.1
Reﬁned residues 725 728
Ligand atoms 62
Waters 616 798
B factors§§ (A˚2)
Protein 33.0 26.0
Ligand 55.1
Water 42.2 33.9
R.m.s deviations
Bond lengths (A˚) 0.009 0.010
Bond angles () 1.2 1.2
Ramachandran plot analysis}} (% of residues)
Most favoured 91.0 90.1
Additionally allowed 9.0 9.9
Generously allowed 0 0.
Disallowed 0 0
† I(+) and I() were scaled separately for anomalous data. ‡ Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where I(hkl) is the intensity of reﬂection hkl,
P
hkl is the sum over
all reﬂections and
P
i is the sum over i measurements of the reﬂection. § Phasing power = FH/E, where E is the estimated lack-of-closure error. } Rcullis = lack-of-closure error/
isomorphous difference and is quoted for centric reﬂections only. †† FOM is the overall ﬁgure of merit, deﬁned as the estimated cosine of the phase error. ‡‡ Rcryst =P
hkl

jFobsj  jFcalcj

=
P
hkl jFobsj. §§ The Wilson B factor was estimated by SFCHECK (Vaguine et al., 1999). }} Ramachandran plot analysis was performed by PROCHECK
(Laskowski et al., 1993).
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often ﬁnd the Br sites for structures of this size (see, for
example, Vivoli et al., 2014), the sites in the 3,6-DKMO
anomalous data could not be located, probably owing to a
weak signal caused by the higher mosaicity of the soaked
crystals.
The phases from DMMULTI averaging were used in
REFMAC5 phased reﬁnement (Pannu et al., 1998) to produce
a good-quality map that allowed the building of an apo 3,6-
DKMO atomic model in O (Jones et al., 1991).
The structure of the FMN complex of the overexpressed
3,6-DKMO was solved by MR with the reﬁned structure of the
apoenzyme using MOLREP (Vagin & Teplyakov, 2010). The
structure was reﬁned by REFMAC5 and the model was rebuilt
in Coot (Emsley et al., 2010). BUSTER reﬁnement (Bricogne
et al., 2015) was used for better positioning of the cofactor with
partial occupancy in the enzyme active site. The ﬁgures were
prepared using PyMOL (DeLano, 2002) and CCP4mg
(McNicholas et al., 2011).
3. Results and discussion
3.1. Purification and crystallization
The native 3,6-DKMO crystallized in space group P212121,
with unit-cell parameters a = 55.0, b = 93.4, c = 162.0 A˚. The
crystals that were grown in 50 mM PIPES pH 6.5, 50%
ammonium sulfate (McGhie et al., 1998) contained two
DKMO subunits in the asymmetric unit with a solvent content
of 50%. The crystal of native protein used for Br anomalous
phasing and for multi-crystal averaging belonged to the same
space group, with the different unit-cell parameters a = 54.9,
b = 93.3, c = 140.8 A˚ and with 42% solvent content. The use of
the Takara overexpression system was successful in producing
a good yield of soluble 3,6-DKMO protein in E. coli host cells.
The protein was puriﬁed by nickel-afﬁnity and gel-ﬁltration
chromatography. The best overexpressed protein crystals grew
at 18C from 100 mM HEPES pH 7.0, 20% PEG 3350 in
the presence of 20 mM FMN, 5 mM NADH and 5 mM ()-
camphor. These crystals contained a dimeric 3,6-DKMO
molecule in the asymmetric unit and belonged to space group
P212121, with unit-cell parameters a = 72.8, b= 82.8, c= 149.9 A˚
and with 54% solvent content.
3.2. Quality of the models
The native apo structure was reﬁned to an Rcryst and Rfree
of 17.1 and 22.1%, respectively, for all data in the resolution
range 20–1.9 A˚ without a  cutoff (Table 1). The FMN
complex was reﬁned to an Rcryst and Rfree of 18.5 and 22.1%,
respectively, at 75–1.9 A˚ resolution. The following residues
were not modelled owing to disorder: A1, A128–133, A176–
180, A377–378, B1, B127–135 and B176–179 in the native
structure and A126–135, A176–179, A377–378, B125–135 and
B176–179 in the FMN-complex structure.
The native 3,6-DKMO model also contains 798 water
molecules, several glycerol molecules, four sulfate ions and
two PIPES buffer molecules. The FMN-complex structure
contains two cofactor molecules, with the occupancy of the
cofactor modelled at 0.6, and several polyethylene glycol
molecules of variable length. The two subunits of the native
structure were rebuilt independently. The root-mean-square
deviation (r.m.s.d.) between C positions of the two subunits is
0.23 A˚. The FMN complex structure has been reﬁned with
local NCS restraints implemented in REFMAC5 (Murshudov
et al., 2011). The r.m.s.d. between the C positions of the two
subunits is 0.19 A˚. Both models contain no Ramachandran
outliers as identiﬁed by PROCHECK (Laskowski et al., 1993).
The overall G-factors used as a measure of the stereochemical
quality of the model are 0.2 for the native structure and 0.1
for the FMN complex (PROCHECK) and are better than
expected for the reported resolution. A total of 80 side chains
in the native structure and 92 in the FMN complex structure
were modelled with alternative conformations. The residues
Pro11 and Ala77 are in the cis conformation. Approximately
43% of the 3,6-DKMO amino acids are in -helices, 14% in
-sheets and 5% in 310-helices.
3.3. Overall fold
The 3,6-DKMO monomer is made up from a single domain
with an eight-stranded /-barrel (TIM-barrel) fold which has
the nonprolyl cis-residue Ala77 forming a -bulge in the
middle of -strand 3. The TIM-barrel structure (Banner et al.,
1976; Wierenga, 2001) is one of the most common protein
folds, which can accommodate a variety of functions. Inter-
estingly, according to the SCOP database (Andreeva et al.,
2014), these include at least two superfamilies of FMN-
dependent oxygenases. These are the bacterial luciferase-like
superfamily to which DKMOs belong (for example, luciferase
from V. harveyi; PDB entry 1luc; Fisher et al., 1996) and the
FMN-linked oxidoreductase superfamily (for example, old
yellow enzyme from Thermus scotoductus SA-01; PDB entry
3hgj; Opperman et al., 2010). The 3,6-DKMO enzyme
described in this paper contains two additional -sheets: a
hairpin formed by residues 159–162 and 167–170 and a parallel
two-stranded -sheet formed by residues 259–261 and 320–322
(Fig. 2a).
Two 3,6-DKMO subunits join to form a dimeric molecule
(Fig. 2b) where approximately 3300 A˚2 of solvent-accessible
area is buried upon dimer formation (18% of the solvent-
accessible area of a subunit).
3.4. FMN binding to DKMO
In the course of the puriﬁcation of the 3,6-DKMO enzyme
the cofactor FMN is easily lost, especially if an ammonium
sulfate precipitation step is used in the puriﬁcation procedure,
since the inorganic sulfate competes for the cofactor-binding
site. We attribute the low afﬁnity of the enzyme for the
oxidized form of the cofactor to be owing to the catalytic cycle
of DKMO. The enzyme is likely to have a higher afﬁnity for
the reduced form of the cofactor FMNH2 (FNR), which has a
bent conformation in the isoalloxazine ring. Similarly, a 200-
fold higher afﬁnity for FNR compared with FMN has been
reported for another two-component p-hydroxyphenylacetate
monooxygenase from Acinetobacter baumannii (Sucharitakul
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et al., 2006). The planar FMN, which has
low afﬁnity for the 3,6-DKMO active
site, leaves it to be reduced to FNR by
the FMN reductase. As the FMN
reductase from the CAM plasmid could
not be puriﬁed in signiﬁcant amounts
from P. putida preparations, commer-
cially available NADH-FMN oxidor-
eductase from V. harveyi has
successfully been used for reduction of
the cofactor in activity measurements
(McGhie, 1998). More recently, an E.
coli ﬂavin oxidoreductase was used to
form a functional assembly with type II
DKMOs (Kadow et al., 2014).
3.5. FMN cofactor modelling in the
electron density
When the structures of unligated 3,6-
DKMO and the  subunit of the holo
bacterial luciferase (PDB entry 3fgc;
Campbell et al., 2009) are super-
imposed, the FMN ring of luciferase has
steric clashes with the active-site resi-
dues of DKMO. It appears that either
the isoalloxazine ring binds differently
in the DKMO active site or some
conformational changes need to occur
to accommodate the FMN molecule in a
similar orientation.
Multiple attempts to co-crystallize
native DKMO and later the over-
expressed protein with increasing
concentrations of FMN were not very
successful, as the low afﬁnity of the
oxidized cofactor for the 3,6-DKMO
enzyme makes it difﬁcult to achieve
cofactor binding. No conformational
changes were observed in the active site
of FMN-complexed 3,6-DKMO, which
is in agreement with the rigidity of the
TIM-barrel scaffold. The best density
for the cofactor molecule was achieved
when the protein was co-crystallized in
PEG with a large excess (20 mM) of
FMN, the substrate analogue ()-
camphor and NADH. Attempts to use
higher concentrations of cofactor
resulted in the appearance of FMN
crystals in the crystallization wells. A
similarly poor afﬁnity of the cofactor for
the active site was observed in other
reported structures of the bacterial
luciferase-like fold superfamily enzymes
which have either partial occupancy of
FMN as in the V. harveyi luciferase
research papers
Acta Cryst. (2015). D71, 2344–2353 Isupov et al.  Type II Baeyer–Villiger monooxygenase 2349
Figure 2
(a) Amino-acid sequence alignment of 3,6-DKMO with the  subunit of V. harveyi luciferase. The
secondary-structure elements of 3,6-DKMO and luciferase are indicated above and below the
alignment, respectively, as -helices, -helices (310-helices) and -strands. The secondary-structure
assignment and the ﬁgure were produced using ESPript (Robert & Gouet, 2014). (b) A cartoon
representation of the dimeric molecule of 3,6-DKMO showing its classical /-barrel structure. The
FMN cofactor is shown as a stick model. Figs. 2(b), 4(b) and 5 were prepared using CCP4mg
(McNicholas et al., 2011)
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(Campbell et al., 2009) or have B factors which are signiﬁ-
cantly higher than those of neighbouring residues as observed
in the structures of nitrilotriacetate monooxygenase from
Bacillus subtilis and long-chain alkane monooxygenase from
Geobacillus thermodenitriﬁcans (PDB entries 1yw1 and 3b9o;
Bonanno et al., 2005; Li et al., 2008).
Therefore, detailed modelling of the position of the FMN
cofactor in the 3,6-DKMO active site was carried out. When
the native 3,6-DKMO model was positioned in the complex
unit cell and reﬁned by BUSTER (Bricogne et al., 2015) prior
to thee addition of solvent molecules, the weighted Fo  Fc
electron-density maps clearly indicated the presence of the
cofactor and the position of its phosphate group; however, the
density for the isoalloxazine ring and the density for the ribityl
sugar were less well deﬁned (Fig. 3). The electron density
clearly identiﬁes the plane of the cofactor ring, with N5 of
FMN hydrogen-bonded to His10. The cofactor atoms N3, O2
and O4 form hydrogen bonds to the 3,6-DKMO protein
residues in this orientation. The isoalloxazine ring could also
be modelled by a rotation of 180 around the C10—N1 bond;
however, in this case the C7M and C8M C atoms were seen to
badly clash with the protein residues. Subsequent reﬁnement
varying the partial occupancy of the cofactor has indicated
that a cofactor occupancy of 0.6 gives the best ﬁt to both the
2Fo  Fc and Fo  Fc maps.
The poor electron density for FMN observed in the active
site of 3,6-DKMO could indicate disorder related to the exis-
tence of multiple cofactor species created by photoreduction
in the intense synchrotron X-ray beam. This has previously
been reported for other ﬂavin cofactor-containing enzymes
(Røhr et al., 2010). However, the density for the isoalloxazine
ring of the cofactor in 3,6-DKMO appears to be ﬂat and not
butterﬂy-shaped as would be observed for the reduced species.
We therefore consider the effect of photoreduction to be
insigniﬁcant and attribute the poor electron density to the low
afﬁnity of the FMN for the active site of the enzyme.
This observation is supported by our experience with the
structure of a related protein (Isupov & Littlechild, unpub-
lished data), determined at 1.7 A˚ resolution, in which the
FMN is at full occupancy in the active site. In this case the
clear electron density shows that the FMN isoalloxazine ring is
ﬂat, thereby conﬁrming the prevalence of the oxidized species.
This reinforces our interpretation as described above for the
3,6-DKMO since crystals of both enzymes were subjected to a
comparable radiation exposure.
No electron density was observed for the ()-camphor or
the NADH present in the crystallization medium.
3.6. The active site
The FMN cofactor binds in the cleft formed at the
C-terminal side of the TIM barrel (Fig. 2b), with the phos-
phate group involved in hydrogen bonding at the edge of the
cleft and the isoalloxazine ring located deep inside of the cleft
(Figs. 4a and 4b). The adjacent subunit contributes residues
175–180 to the lining of the active-site cavity on the opposite
side of the cleft. This loop is poorly ordered in both the apo
and the complex structures. The isoalloxazine ring makes
hydrogen bonds to the side chains of His10 and Ser44 and the
main-chain O atom of Met76.
The reduced form of the cofactor FMN (FNR) model was
created using JLigand (Lebedev et al., 2012), with the FNR
research papers
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Figure 3
A stereo diagram of the active site of 3,6-DKMO viewed from the solvent region. The cofactor FMN, modelled with an occupancy of 0.6, and
neighbouring residues are shown as stick models. The positive OMIT Fo  Fc electron-density map contoured at 3.0 is shown in green and the negative
Fo  Fc map contoured at 3.0 is shown in red. The OMIT difference electron density was calculated by BUSTER using a structure from which all solvent
and cofactor molecules had been removed and the model reﬁned to reduce the bias. The ﬁgure was prepared using PyMOL (DeLano, 2002).
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isoalloxazine ring modelled with a 20 deviation from
planarity, as observed in the structure of another luciferase-
like fold superfamily enzyme, the F420-dependent secondary
alcohol dehydrogenase enzyme (PDB entry 1rhc; Aufhammer
et al., 2004), and several other reduced ﬂavin cofactor-
containing structures. The FNR model was positioned into the
active site of 3,6-DKMO, where it appears to retain the
hydrogen bonding observed for the oxidized FMN (Fig. 4a)
but makes additional favourable hydrophobic interactions
with the side chains of Phe203 and Ile223. These interactions
would favour the higher afﬁnity of the enzyme for the reduced
form of the cofactor.
The catalytic reaction occurs on the si side of the isoallox-
azine ring, which is consistent with the mechanism of other
bacterial luciferase-like fold enzymes, but contradicts the
predictions previously made for the P. putida type II BVMOs
(Kelly, 1996).
3.7. Comparison with other bacterial luciferase-family
proteins
The dimer structure is conserved throughout the bacterial
luciferase-like superfamily of TIM-barrel proteins and its
conservation was used for macromolecular phasing of 3,6-
DKMO (Isupov & Lebedev, 2008). Enzymes belonging to the
other superfamily of TIM-barrel fold FMN-linked oxido-
reductases also form dimers and occasionally higher oligo-
mers, but these dimers are organized differently.
The closest structural homologue to 3,6-DKMO among
known structures is subunit A of V. harveyi luciferase (PDB
entry 1luc; Fisher et al., 1996), which can be superimposed with
the 3,6-DKMO structure with an r.m.s.d. of 2.2 A˚ for 292 C
atoms of 362, as calculated by Coot (Emsley et al., 2010).
Superimposition of the 3,6-DKMO enzyme monomer C
positions with the FMN-dependent long-chain alkane mono-
oxygenase (PDB entry 3b9o; Li et al., 2008) over 299 residues
gives an estimated r.m.s.d. of 2.6 A˚. The subunit of the F420-
dependent secondary dehydrogenase enzyme (PDB entry
research papers
Acta Cryst. (2015). D71, 2344–2353 Isupov et al.  Type II Baeyer–Villiger monooxygenase 2351
Figure 4
(a) A schematic drawing of the interactions of the FMN in the active site
of 3,6-DKMO. The ﬁgure was prepared by LigPlot+ (Laskowski &
Swindells, 2011). (b) The electrostatic potential surface calculated for the
subunit of 3,6-DKMO. Positive charge is shown in blue and negative
charge in red. The active-site cavity can be seen in the centre of the ﬁgure.
The cofactor FMN molecule is shown as a stick model at the bottom of
the active-site pocket.
Figure 5
A diagram showing the different orientation of the isoalloxazine ring of
the FMN cofactor in the active sites of the superimposed  subunit of the
bacterial luciferase and the 3,6-DKMO enzyme. The C backbones of
luciferase and 3,6-DKMO are shown in ice blue and purple, respectively.
The C atoms in the FMN cofactors are shown in yellow and green for
luciferase and 3,6-DKMO, respectively.
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1rhc; Aufhammer et al., 2004) can be superimposed with an
r.m.s.d. of 2.8 A˚ over 280 residues.
Known structures of FMN- and F420-dependent enzymes
have a consistent orientation of their tricyclic cofactor rings
within the clefts of their active sites (Aufhammer et al., 2004,
2005; Bonanno et al., 2005; Li et al., 2008; Campbell et al.,
2009). The orientation of the isoalloxazine ring in the active
site of 3,6-DKMO is nearly normal to the planes of the
tricyclic cofactor rings observed in known structures of the
bacterial luciferase-like fold superfamily enzymes, as illu-
strated in Fig. 5 for the bacterial luciferase  subunit. Despite
this difference in the orientation of the cofactor ring, all
enzymes of the bacterial luciferase superfamily catalyse their
reaction on the si side of the ring.
3.8. The reaction mechanism
The catalytic activity of the type II BMVOs is carried out
mainly through the prosthetic FMN group. This cofactor binds
in the enzyme active site in the FNR form, which undergoes
attack by molecular oxygen at C4A of the isoalloxazine ring
and becomes 4-hydroperoxyﬂavin (FMN-OOH). This reac-
tion is similar to that described for the ﬂavin-containing
monooxygenase from Schizosaccharomyces pombe (Eswara-
moorthy et al., 2006). The active-site residues are required for
positioning of the substrate in a catalytic position in relation to
the cofactor. Since there is a variation of the position of the
cofactor isoalloxazine ring between 3,6-DKMO and the other
proteins of the bacterial luciferase family, there is little
conservation of the active-site residues within this enzyme
family. Even the closely related 3,6- and 2,5-DKMOs have
only two conserved residues lining the active-site cavity, which
are His46 and Glu52 in 3,6-DKMO numbering. These are not
conserved within the protein family. The residues His10 and
Ser44 which are involved in FMN isoalloxazine ring binding
in 3,6-DKMO are not conserved in 2,5-DKMO, implying a
different mode of cofactor binding in this related enzyme.
3.9. Nonprolyl cis-peptide b-bulge
A common feature of many bacterial luciferase-like fold
superfamily enzymes is a nonprolyl cis-peptide forming a bulge
in the middle of 3 which was proposed to be important for
catalytic activity (Aufhammer et al., 2005). This feature is not
present in the nitrilotriacetate monooxygenase and long-chain
alkane monooxygenase (Bonanno et al., 2005; Li et al., 2008).
The importance of the nonprolyl cis-peptide -bulge seems to
be conﬁrmed in the 3,6-DKMO structure, where this bulge is
formed by residues Met76 and cis Ala77, with the main-chain
O atom of Met76 and N atom of Ala77 contributing to the
binding of the FMN ring.
3.10. Interaction with the flavin reductase
The FMN reductase activity is required for the 3,6-DKMO
reaction. When native 3,6-DKMO was puriﬁed from camphor-
induced cells of P. putida, high enzymatic activity was
observed in the crude extract (McGhie & Littlechild, 1996;
McGhie et al., 1998). This activity was present for the partially
puriﬁed enzyme; however, it was lost in the later stages of
puriﬁcation of the oxygenating component. This led to the
conclusion (McGhie et al., 1998) that the oxygenating
component forms a transient multienzyme complex with a
speciﬁc P. putida ﬂavin reductase. The commercially available
Vibrio ﬂavin reductase (Sigma–Aldrich) was able to demon-
strate activity with the puriﬁed 3,6-DKMO oxygenating
enzyme in biotransformation reactions (McGhie, 1998). More
recently, it has been reported (Kadow et al., 2014) that one of
the ﬂavin reductases present in E. coli is able to catalyse the
FMN reduction with both 3,6- and 2,5-DKMOs. Partial
sequencing of the large CAM plasmid has now identiﬁed a
ﬂavin reductase adjacent to the 3,6-DKMO gene on the CAM
plasmid (Littlechild & Isupov, unpublished data), and studies
are ongoing to reconstitute the putative multienzyme complex
in a stable form to allow its structural characterization.
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